CBD NEWS

A revolutionary step in the world of CBD and nutraceuticals

Forchronic and Cannapro Europe have joined forces and formed a Joint Venture that will bring Forchronic's innovative product, CBD Plus, to international markets. This biotech-engineered product doubles the bioavailability of organic CBD (cannabidiol), opening new doors in the field of disease relief and treatment.

With the nutraceuticals market projected to grow 50% through 2028 globally, with an estimated annual increase of 8.6% over the next seven years*, the cannabidiol boom is here to stay. This market is expected to reach a value of $56.2 billion by 2028, driven by growing demand for CBD-based products and FDA approval of its use as a legal additive.

In this panorama of transformation, Forchronic's CBD Plus emerges as an innovative product. With an amazing bioavailability of 97%, this product is presented as the result of a patented technology of bioactive compounds vehiculization, which ensures maximum absorption in the body. A multidisciplinary team composed of experts from Forchronic, as well as prestigious institutions such as UAM, CIAL and IMDEA Alimentación, have made this scientific achievement possible.

In the words of Enrique Sainz, CEO of Forchronic: "We are excited to announce this strategic partnership with Cannapro Europe. Our goal is to bring CBD Plus internationally and enhance the medicinal properties of CBD by improving its bioavailability. We strongly believe in the potential of this growing market and the positive impact that our product can have on people's health and wellbeing.

The alliance of Forchronic and Cannapro Europe will open new doors in the field of nutraceuticals and improve the quality of life of those suffering from a disease. In addition, the opportunity to invest in this line of development on an international scale is open to investment partners who wish to be part of this project.

.

MORE INFORMATION

CBD Plus

Forchronic, with the collaboration of the UAM, CIAL and IMDEA Alimentación, has developed a new product new product that doubles the bioavailability of Cannabidiol (CBD).

With an innovative PATENTED technology of VEHICULIZATION OF BIOACTIVE COMPOUNDS that offers MAXIMUM
bioavailability and absorption of the product in the body.

This product is a real revolution in the Cannabidol sector. Cannabidol because it can significantly lower production costs.

10 - 50%

BIOAVAILABILITY OF COMMERCIAL CBD

According to the form of administration

CBD AVAILABILITY + OUR VEHICLE
0 %
The developed vehicle DUPLICATES the bioavailability of CBD.

BUSINESS OPPORTUNITY

The demand for CBD-based products is increasing due to its healing properties.

There is a need for a product that improves the bioavailability of CBD and can enhance its medicinal and cosmetic properties.

Currently, the CBD available
on the market has a low
bioavailability. The quality
currently on the market is not good.

Only 10% of the CBD marketed is organic, due to its scarcity and high prices.